中文
English
한국어
日本語
Español
Français
Русский
| 카탈로그 번호 | HF941056 |
|---|---|
| 종 반응성 | Human |
| 응용 분야 | ELISA, Functional assay, Research in vivo |
| 클론성 | Monoclonal |
| 이소타입 | Tumor Necrosis Factor Receptor superfamily protein TNFRSF13b fusion with IgG1 Fc Fragment. |
| 생물학적 활성 | Povetacicept (0.137-33.3 nM; 240-1800 s) binds to recombinant human APRIL with a K d value of 1.00 pM, and also binds to recombinant human BAFF with a K d value of 59.3 pM, exhibiting high-affinity dual binding activity toward these two cytokines [2]. Povetacicept (2.5 pM-200 nM; 5 h) potently inhibits the signaling pathways of APRIL, BAFF, BAFF 60-mer and BAFF/APRIL heterotrimer in TACI/Jurkat/NF-κB reporter cells [2]. Povetacicept (7 d) potently inhibits the proliferation of primary human B cells, the differentiation of class-switched memory B cells into plasma cells, and the secretion of immunoglobulins [2]. Parmacokinetics Species Dose Route C max AUC Cynomolgus Monkey [2] 9 mg/kg i.v. 27 ug/mL 1167 ug·h/mL Povetacicept (10 mg/kg; i.p.; twice weekly; 3.5 weeks) significantly reduces bone marrow antibody-secreting cell counts, suppresses autoantibody production, and increases hematocrit in an HOD + OTII + mouse model of AIHA [1]. Povetacicept (15 mg/kg; i.p.; 2 doses (days 4 and 11)) potently reduces splenic immune cell subsets and inhibits T cell-dependent antibody formation more effectively than WT TACI-Fc comparators in KLH-immunized mice [2]. Povetacicept (10 mg/kg; i.p.; 2 doses (days 1 and 6)) exhibits superior immunosuppressive activity over single-target inhibitors, combination therapy, telitacicept, and anti-CD20 in SRBC-immunized mice, leading to greater suppression of T cell-dependent antibody responses [2]. Povetacicept (17 mg/kg; i.p.; twice weekly; 20 weeks) significantly suppresses lupus disease activity, improves survival, and reduces renal and glandular pathology in the spontaneous NZB/NZW F1 lupus mouse model [2]. Povetacicept (10 mg/kg; i.p.; twice weekly; day 5 to day 88) significantly suppresses renal immune deposition and reduces pathogenic splenic immune cell subsets in the inducible bm12 lupus mouse model [2]. |
| 발현 시스템 | Mammalian cells |
| 타겟 | TNF- and APOL-related leukocyte expressed ligand 2, APRIL, CD256, Tumor necrosis factor ligand superfamily member 13, TNF-related death ligand 1, TALL-2, TNFSF13, ZTNF2, A proliferation-inducing ligand, TALL2, TRDL-1, BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor |
| 내독소 수준 | < 10 EU/mg |
| 순도 | >95% purity as determined by SDS-PAGE. |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 등록번호 | O75888 & Q9Y275 |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS pH 7.4 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 대체 이름 | ALPN-303, povetacicept |
| 배경 | Povetacicept (ALPN-303), an Fc fusion protein of an engineered TACI domain, is a dual APRIL/BAFF antagonist. Povetacicept modulates B lymphocytes and pathogenic autoantibodies for the study of Lupus and other B cell-related autoimmune diseases. |
| 참고 문헌 | 1. Stacey Dillon, et al. Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice. Front. Immunol., 06 June 2025. [HF941056] 2. Evans LS, et al. Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases. Arthritis Rheumatol. 2023;75(7):1187-1202. [HF941056] 3. Rinaldi E, et al. Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice. Front Immunol. 2025;16:1533093. Published 2025 Jun 6. [HF941056] |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |
SDS-PAGE for Research Grade Povetacicept
+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206
